Gilead Sciences (NASDAQ:GILD) Updates FY22 Earnings Guidance

Gilead Sciences (NASDAQ:GILDGet Rating) issued an update on its FY22 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $6.20-$6.70 for the period, compared to the Thomson Reuters consensus estimate of $6.50.

Several equities analysts have recently commented on GILD shares. Truist Financial lowered their target price on Gilead Sciences from $77.00 to $75.00 and set a hold rating for the company in a report on Wednesday, February 2nd. Royal Bank of Canada upped their target price on Gilead Sciences from $76.00 to $77.00 and gave the company an outperform rating in a report on Tuesday, April 12th. Barclays lowered their target price on Gilead Sciences from $63.00 to $56.00 and set an underweight rating for the company in a report on Thursday, March 10th. Maxim Group lowered their target price on Gilead Sciences from $88.00 to $84.00 in a report on Thursday, February 3rd. Finally, Morgan Stanley decreased their price objective on Gilead Sciences from $69.00 to $63.00 and set an equal weight rating for the company in a report on Tuesday, April 12th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of Hold and an average target price of $73.38.

NASDAQ GILD traded down $2.22 on Friday, reaching $59.34. 10,455,777 shares of the stock traded hands, compared to its average volume of 7,446,111. Gilead Sciences has a 12 month low of $57.19 and a 12 month high of $74.12. The firm’s fifty day simple moving average is $60.53 and its 200 day simple moving average is $65.68. The company has a market cap of $74.41 billion, a price-to-earnings ratio of 16.58, a P/E/G ratio of 0.44 and a beta of 0.40. The company has a quick ratio of 1.13, a current ratio of 1.27 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILDGet Rating) last announced its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported $2.12 EPS for the quarter, beating analysts’ consensus estimates of $1.80 by $0.32. Gilead Sciences had a return on equity of 45.27% and a net margin of 22.80%. The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.28 billion. During the same quarter in the prior year, the firm earned $2.08 EPS. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. As a group, equities research analysts forecast that Gilead Sciences will post 6.54 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, March 30th. Stockholders of record on Tuesday, March 15th were given a dividend of $0.73 per share. This represents a $2.92 dividend on an annualized basis and a dividend yield of 4.92%. The ex-dividend date of this dividend was Monday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.71. Gilead Sciences’s dividend payout ratio is 81.56%.

In other news, EVP Brett A. Pletcher sold 1,691 shares of the stock in a transaction on Wednesday, February 9th. The stock was sold at an average price of $63.89, for a total value of $108,037.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Brett A. Pletcher sold 3,634 shares of the stock in a transaction on Friday, March 11th. The shares were sold at an average price of $58.24, for a total value of $211,644.16. The disclosure for this sale can be found here. Insiders have sold a total of 19,386 shares of company stock valued at $1,283,423 in the last quarter. Insiders own 0.16% of the company’s stock.

Several large investors have recently made changes to their positions in GILD. First Community Trust NA purchased a new stake in shares of Gilead Sciences during the fourth quarter worth $34,000. EverSource Wealth Advisors LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter worth $76,000. Levin Capital Strategies L.P. bought a new position in Gilead Sciences during the fourth quarter valued at about $203,000. Titleist Asset Management LTD. acquired a new stake in shares of Gilead Sciences in the fourth quarter worth about $208,000. Finally, Privium Fund Management UK Ltd acquired a new position in shares of Gilead Sciences during the 4th quarter valued at about $210,000. Institutional investors and hedge funds own 79.00% of the company’s stock.

About Gilead Sciences (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Featured Stories

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.